If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Several artificial nucleobases have been synthesized, and successfully incorporated in the eight-base DNA analogue named Hachimoji DNA. Dubbed S, B, P, and Z, these artificial bases are capable of bonding with each other in a predictable way (S–B and P–Z), maintain the double helix structure of DNA, and be transcribed to RNA. Their existence could be seen as an indication that there is nothing special about the four natural nucleobases that evolved on Earth. On the other hand, DNA is tightly related to RNA which does not only act as a transcript of DNA but also performs as molecular machines many tasks in cells. For this purpose it has to fold into a structure. It has been shown that to allow to create all possible structures at least four bases are required for the corresponding RNA, while a higher number is also possible but this would be against the natural principle of least effort.
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Isotopic compositions and standard atomic masses from: de Laeter, John Robert; Böhlke, John Karl; De Bièvre, Paul; Hidaka, Hiroshi; Peiser, H. Steffen; Rosman, Kevin J. R.; Taylor, Philip D. P. (2003). "Atomic weights of the elements. Review 2000 (IUPAC Technical Report)". Pure and Applied Chemistry. 75 (6): 683–800. doi:10.1351/pac200375060683. Wieser, Michael E. (2006). "Atomic weights of the elements 2005 (IUPAC Technical Report)". Pure and Applied Chemistry. 78 (11): 2051–2066. doi:10.1351/pac200678112051. "News & Notices: Standard Atomic Weights Revised". International Union of Pure and Applied Chemistry. 19 October 2005. Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
Danuglipron is a small-molecule GLP-1 receptor agonist, formerly under development by Pfizer that, in an oral formulation, was under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting. However, in April 2025, Pfizer announced it would abandon further development of danuglipron due to unpredictable liver toxicity.
=== Allosteric site transporter substrates === Alternatively, some reuptake inhibitors bind to allosteric sites and inhibit reuptake indirectly and noncompetitively. Phencyclidine and related drugs such as benocyclidine, tenocyclidine, ketamine, and dizocilpine (MK-801), have been shown to inhibit the reuptake of the monoamine neurotransmitters. They appear to exert their reuptake inhibition by binding to vaguely characterized allosteric sites on each of the respective monoamine transporters. Benztropine, mazindol, and vanoxerine also bind to these sites and have similar properties. In addition to their high affinity for the main site of the monoamine transporters, several competitive transporter substrates such as cocaine and indatraline have lower affinity for these allosteric sites as well. A few of the selective serotonin reuptake inhibitors (SSRIs) such as the dextro-enantiomer of citalopram appear to be allosteric reuptake inhibitors of serotonin. Instead of binding to the active site on the serotonin transporter, they bind to an allosteric site, which exerts its effects by causing conformational changes in the transporter protein and thereby modulating the affinity of substrates for the active site. As a result, escitalopram has been marketed as an allosteric serotonin reuptake inhibitor. Notably, this allosteric site may be directly related to the above-mentioned PCP binding sites.
Sources: en.wikipedia.org
Affinity purification purifies proteins by retaining them on a column through their affinity to antibodies, enzymes, or receptors that have been immobilised on the column. Filtration is a mechanical method to separate solids from liquids or gases by passing the feed stream through a porous sheet such as a cloth or membrane, which retains the solids and allows the liquid to pass through. Centrifugation is a process that uses an electric motor to spin a vessel of fluid at high speed to make heavier components settle to the bottom of the vessel. Evaporation removes volatile liquids from non-volatile solutes, which cannot be done through filtration due to the small size of the substances. Liquid–liquid extraction removes an impurity or recovers a desired product by dissolving the crude material in a solvent in which other components of the feed material are soluble. Crystallization separates a product from a liquid feed stream, often in extremely pure form, by cooling the feed stream or adding precipitants that lower the solubility of the desired product so that it forms crystals. The pure solid crystals are then separated from the remaining liquor by filtration or centrifugation. Recrystallization: In analytical and synthetic chemistry work, purchased reagents of doubtful purity may be recrystallised, e.g. dissolved in a very pure solvent, and then crystallized, and the crystals recovered, in order to improve and/or verify their purity. Trituration removes highly soluble impurities from usually solid insoluble material by rinsing it with an appropriate solvent.
== Function == mTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue, and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12. The FKBP12–rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.
==== Don Cossacks in World War II ==== In April 1936, the earlier ban on Cossacks serving in the Red Army was lifted. Later in 1936, two existing Red Army cavalry divisions were re-designated as Don Cossacks. In 1939, a number of these regiments were issued with traditional Cossack uniforms, in ceremonial and field service versions. The dress of the Don Cossack units included dark-blue breeches with broad red stripes which had distinguished them prior to the Revolution. The Don Cossack Cavalry Corps saw extensive active service until 1943, after which its role diminished, as did that of the other remaining horse-mounted units in the Red Army. However Don Cossack cavalry was still in existence in 1945 and participated in the Victory Parade in Moscow. During World War II, the Don Cossacks mustered the largest single concentration of Cossacks within the German Army, the XVth SS Cossack Cavalry Corps, a great part of them former Soviet citizens. The XVth SS Cossack Cavalry Corps included the 1st Cossack Division and the 2nd Cossack Division. The majority of the Cossacks remained loyal to the Red Army. In the earliest battles, particularly the encirclement of Belostok, Cossack units such as the 94th Beloglisnky, 152nd Rostovsky and 48th Belorechensky regiments fought to their death. In the opening phase of the war, during the German advance towards Moscow, Cossacks were extensively used for raids behind enemy lines.
== In plants == Approximately 30 GRX isoforms are described in the model plant Arabidopsis thaliana and 48 in Oryza sativa L. According to their redox-active centre, they are subgrouped in six classes of the CSY[C/S]-, CGFS-, CC-type and 3 groups with additional domains of unknown function. The CC-type GRXs are only found in higher plants. In Arabidopsis, GRXs are involved in flower development and Salicylic acid signalling.
Drug packaging (or pharmaceutical packaging) is process of packing pharmaceutical preparations for distribution, and the physical packaging in which they are stored. It involves all of the operations from production through drug distribution channels to the end consumer. Pharmaceutical packaging is highly regulated but with some variation in the details, depending on the country of origin or the region. Several common factors can include: assurance of patient safety, assurance of the efficacy of the drug through the intended shelf life, uniformity of the drug through different production lots, thorough documentation of all materials and processes, control of possible migration of packaging components into the drug, control of degradation of the drug by oxygen, moisture, heat, light exposure etc., prevention of microbial contamination, sterility, etc. Packaging is often involved in dispensing, dosing, and use of the pharmaceutical product. Communication of proper use and cautionary labels are also regulated. Packaging is an integral part of pharmaceutical product.
Sources: en.wikipedia.org
== Application in surface science == Static SIMS has been used in the investigation of the initial process of oxidation where only the first two or three metal layers participate in the oxidation. Static SIMS gives a rigorous test of surface cleanliness, as it can detect species at ppm concentrations. Static SIMS is used in the investigation of the nature of adsorption (molecular or dissociative). For example, dissociative adsorption of CO on a metal surface (M) is characterized by MC+, MO+, M2O+, and M2C+ secondary ions (Fe and W), and molecular adsorption is identified by MCO+ and M2CO+ ions (Cu, Pd, Ni and Fe). Similarly, it also helps in the investigation of binding energies, chemical structure of the adsorbate, interaction between adsorbate molecules, and reactivity of adsorbate.
The World Health Organization in 1987 found that comfortable indoor temperatures of 18–24 °C (64–75 °F) were not associated with health risks for healthy adults with appropriate clothing, humidity, and other factors. For infants, elderly, and those with significant health problems, a minimum of 20 °C (68 °F) was recommended. Temperatures lower than 16 °C (61 °F) with humidity above 65% were associated with respiratory hazards including allergies. The WHO's 2018 guidelines give a strong recommendation that a minimum of 18 °C (64 °F) is a "safe and well-balanced indoor temperature to protect the health of general populations during cold seasons". A higher minimum temperature may be necessary for vulnerable groups including children, the elderly, and people with cardiorespiratory disease and other chronic illnesses. However, the recommendation regarding risk of exposure to high indoor temperatures is only "conditional". Minimal-risk high temperatures range from about 21 to 30 °C (70 to 86 °F) depending on the region, with maximum acceptable temperatures between 25 and 32 °C (77 and 90 °F).
Beriglobin P, human hepatitis A immunoglobulin, liquid 16% solution for intramuscular injection Berirab P, human rabies immunoglobulin, liquid 16% solution for intramuscular injection Carimune NF, Sandoglobulin, Sanglopor human normal immunoglobulin, freeze-dried formulations for intravenous administration Cytogam, human cytomegalovirus immunoglobulin. Liquid immunoglobulin containing a standardized amount of antibody to cytomegalovirus. Hepatitis B Immunoglobulin P Behring, human hepatitis B immunoglobulin, liquid 16% solution for intramuscular injection Hizentra, Human normal immunoglobulin. Liquid 20% immunoglobulin solution, ready-to-use for subcutaneous administration Privigen, human polyvalent immunoglobulin, liquid 10% solution for intravenous injection Rhesogamma P, human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection. Rhophylac human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection. Sandoglobulin NF Liquid, Redimune, Redimune NF Liquid, human normal immunoglobulin, liquid 12% solution for intravenous administration Tetagam P, human tetanus immunoglobulin, liquid 16% solution for intramuscular injection Varicellon P, human varicella immunoglobulin, liquid 16% solution for intramuscular injection Vivaglobin, human normal immunoglobulin, liquid 16% solution for subcutaneous administration Coagulation/Bleeding Disorders:
In January 1868, when the new port of Kobe opened east of Hyogo Port, the Kobe foreign settlement was established. In 1868, Englishman Edward Charles Kirby established the first slaughterhouse in Kobe, and in 1869, a sukiyaki restaurant called "Gekka-tei" opened there. According to a newspaper article in 1875, Kobe was the first place where meat eating was popular, with 800 cows slaughtered in a month. Next was Yokohama with 600, followed by Tokyo with 500, and Osaka and Nagoya with 300. The reputation of Wagyu beef as having a superior taste spread from the residents of the foreign settlement to the Japanese, and it was written in books of the time that "Wagyu beef has a better taste than foreign beef" and "there has never been beef as good as Kobe's beef". At the same time, however, it was also believed that Wagyu were superior to Western breeds for plowing use but inferior in milk and meat production, and their improvement was urgently needed. Between 1868, the year of the Meiji Restoration, and 1887, some 2600 foreign cattle were imported. At first, there was little interest in cross-breeding these with the native stock, but from about 1900, it became widespread. In 1900, the Japanese government established a committee to investigate the improvement of cattle breeding, and began a systematic crossbreeding program between Wagyu and Western breeds.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.